234 related articles for article (PubMed ID: 11145092)
21. BSEP inhibition: in vitro screens to assess cholestatic potential of drugs.
Kis E; Ioja E; Rajnai Z; Jani M; Méhn D; Herédi-Szabó K; Krajcsi P
Toxicol In Vitro; 2012 Dec; 26(8):1294-9. PubMed ID: 22120137
[TBL] [Abstract][Full Text] [Related]
22. Cholestasis.
Elferink RO
Gut; 2003 May; 52 Suppl 2(Suppl 2):ii42-8. PubMed ID: 12651881
[TBL] [Abstract][Full Text] [Related]
23. Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.
Paumgartner G
World J Gastroenterol; 2006 Jul; 12(28):4445-51. PubMed ID: 16874853
[TBL] [Abstract][Full Text] [Related]
24. Generation of a bile salt export pump deficiency model using patient-specific induced pluripotent stem cell-derived hepatocyte-like cells.
Imagawa K; Takayama K; Isoyama S; Tanikawa K; Shinkai M; Harada K; Tachibana M; Sakurai F; Noguchi E; Hirata K; Kage M; Kawabata K; Sumazaki R; Mizuguchi H
Sci Rep; 2017 Feb; 7():41806. PubMed ID: 28150711
[TBL] [Abstract][Full Text] [Related]
25. Hepatocellular transporters and cholestasis.
Pauli-Magnus C; Meier PJ
J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S103-10. PubMed ID: 15758645
[TBL] [Abstract][Full Text] [Related]
26. Dubin-Johnson syndrome and intrahepatic cholestasis of pregnancy in a Sri Lankan family: a case report.
Kularatnam GAM; Warawitage D; Vidanapathirana DM; Jayasena S; Jasinge E; de Silva N; Liyanarachchi KLAMS; Wickramasinghe P; Devgun MS; Barbu V; Lascols O
BMC Res Notes; 2017 Sep; 10(1):487. PubMed ID: 28923092
[TBL] [Abstract][Full Text] [Related]
27. Progressive familial intrahepatic cholestasis type 1.
Paulusma CC; Elferink RP; Jansen PL
Semin Liver Dis; 2010 May; 30(2):117-24. PubMed ID: 20422494
[TBL] [Abstract][Full Text] [Related]
28. Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis.
Meng Q; Chen XL; Wang CY; Liu Q; Sun HJ; Sun PY; Huo XK; Liu ZH; Yao JH; Liu KX
Toxicol Appl Pharmacol; 2015 Mar; 283(3):178-86. PubMed ID: 25655198
[TBL] [Abstract][Full Text] [Related]
29. Progressive familial intrahepatic cholestasis.
Cavestro GM; Frulloni L; Cerati E; Ribeiro LA; Corrente V; Sianesi M; Franzè A; Di Mario F
Acta Biomed; 2002; 73(3-4):53-6. PubMed ID: 12596388
[TBL] [Abstract][Full Text] [Related]
30. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
31. [New molecular aspects of cholestatic liver diseases].
Trauner M; Fickert P; Stauber RE
Z Gastroenterol; 1999 Jul; 37(7):639-47. PubMed ID: 10458013
[TBL] [Abstract][Full Text] [Related]
32. [New molecular features of cholestatic diseases of the liver].
Méndez-Sánchez N; Chavez-Tapia NC; Uribe M
Rev Invest Clin; 2003; 55(5):546-56. PubMed ID: 14968476
[TBL] [Abstract][Full Text] [Related]
33. [Liver disease associated with hereditary defects of hepatobiliary transporters].
Wendum D
Ann Pathol; 2010 Dec; 30(6):426-31. PubMed ID: 21167428
[TBL] [Abstract][Full Text] [Related]
34. Genetics of familial intrahepatic cholestasis syndromes.
van Mil SW; Houwen RH; Klomp LW
J Med Genet; 2005 Jun; 42(6):449-63. PubMed ID: 15937079
[TBL] [Abstract][Full Text] [Related]
35. The bile salt export pump (BSEP) in health and disease.
Kubitz R; Dröge C; Stindt J; Weissenberger K; Häussinger D
Clin Res Hepatol Gastroenterol; 2012 Dec; 36(6):536-53. PubMed ID: 22795478
[TBL] [Abstract][Full Text] [Related]
36. The bile salt export pump: molecular properties, function and regulation.
Arrese M; Ananthanarayanan M
Pflugers Arch; 2004 Nov; 449(2):123-31. PubMed ID: 15578267
[TBL] [Abstract][Full Text] [Related]
37. Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis.
Noe J; Kullak-Ublick GA; Jochum W; Stieger B; Kerb R; Haberl M; Müllhaupt B; Meier PJ; Pauli-Magnus C
J Hepatol; 2005 Sep; 43(3):536-43. PubMed ID: 16039748
[TBL] [Abstract][Full Text] [Related]
38. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis.
Gomez-Ospina N; Potter CJ; Xiao R; Manickam K; Kim MS; Kim KH; Shneider BL; Picarsic JL; Jacobson TA; Zhang J; He W; Liu P; Knisely AS; Finegold MJ; Muzny DM; Boerwinkle E; Lupski JR; Plon SE; Gibbs RA; Eng CM; Yang Y; Washington GC; Porteus MH; Berquist WE; Kambham N; Singh RJ; Xia F; Enns GM; Moore DD
Nat Commun; 2016 Feb; 7():10713. PubMed ID: 26888176
[TBL] [Abstract][Full Text] [Related]
39. Combined mutations of canalicular transporter proteins cause severe intrahepatic cholestasis of pregnancy.
Keitel V; Vogt C; Häussinger D; Kubitz R
Gastroenterology; 2006 Aug; 131(2):624-9. PubMed ID: 16890614
[TBL] [Abstract][Full Text] [Related]
40. Model Systems for Studying the Role of Canalicular Efflux Transporters in Drug-Induced Cholestatic Liver Disease.
Stieger B; Mahdi ZM
J Pharm Sci; 2017 Sep; 106(9):2295-2301. PubMed ID: 28385542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
